← Leaderboards
William Robert Jarnagin
Sloan-Kettering Inst Can Research
$4,049,789
Attributed
$9,360,433
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–24$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,360,433 · 4
By mechanism
R01$5,471,936 · 2
U01$3,264,005 · 1
R21$624,492 · 1
Top collaborators
- Michael Ian Miga12 shared
- Andrea Cercek5 shared
- Christine A Iacobuzio-Donahue5 shared
- James David Stefansic2 shared
- Logan Clements1 shared
- Michael Scherer1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Richard Kinh Gian Do$1,284,179
- Amber Simpson$1,284,179
- Andrea Cercek$4,410,417
- Yun Shin Chun$1,158,484
- Sarat Chandarlapaty$10,852,142
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTumorImageLiverOperative Surgical ProceduresExcisionBaseIncidenceMalignant Neoplasm Of LiverUnresectableGoldSurvival RateDisease ManagementDoseHeterogeneityHepaticMinimally InvasiveEvaluationInvestigationProspectiveChemotherapyEnrollmentMorbidity - Disease RateRandomized
Grant awards (19)
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$623,923
U01 · FY2024 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$642,310
U01 · FY2023 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$649,386
U01 · FY2022 · CA · contact PI
Deformation Corrected Image Guided Laparoscopic Liver Surgery$572,086
R01 · FY2022 · EB
Deformation Corrected Image Guided Laparoscopic Liver Surgery$74,485
R01 · FY2022 · EB
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$665,665
U01 · FY2021 · CA · contact PI
Deformation Corrected Image Guided Laparoscopic Liver Surgery$561,763
R01 · FY2021 · EB
Deformation Corrected Image Guided Laparoscopic Liver Surgery$74,485
R01 · FY2021 · EB
Deformation Corrected Image Guided Laparoscopic Liver Surgery$37,182
R01 · FY2021 · EB
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$682,721
U01 · FY2020 · CA · contact PI
Deformation Corrected Image Guided Laparoscopic Liver Surgery$595,560
R01 · FY2020 · EB
Deformation Corrected Image Guided Laparoscopic Liver Surgery$582,865
R01 · FY2019 · EB
Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery$586,385
R01 · FY2015 · CA
Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery$598,130
R01 · FY2014 · CA
Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery$581,471
R01 · FY2013 · CA
Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery$637,268
R01 · FY2012 · CA
Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery$570,256
R01 · FY2011 · CA
Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy$312,246
R21 · FY2008 · CA · contact PI
Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy$312,246
R21 · FY2007 · CA · contact PI